May 24, 2018
TOKYO, JAPAN - May 24, 2018 - Terumo Corporation (TSE: 4543) announced today that it has launched the Ultimaster™ Tansei™ drug eluting stent (DES) in Europe during EuroPCR 2018, the World's Leading Cardiovascular Intervention Course, with the interim results of large scale clinical trials. Terumo aims to achieve the global revenue of 22 billion yen in the fiscal year ending March 31, 2019 as a whole DES.
Furthering Terumo's core philosophy of developing technologies that address unmet needs, the introduction of the Ultimaster Tansei DES allows physicians to reach and treat complex anatomies both with radial and femoral access with confidence based on the results of comprehensive clinical program of Ultimaster DES. The improvements made on the tip and shaft will facilitate stent delivery in complex lesions and enhance Ultimaster Tansei usability, making easier stent navigability through the blood vessels by creating the experience of exceptional pushability.
During EuroPCR 2018, the world's leading cardiovascular intervention course held in Paris (France), the Ultimaster Tansei was used in live demonstration cases.
"During the live-case transmissions yesterday, I implanted four Ultimaster Tansei stents from Terumo", said Dr. Jean Fajadet, Interventional Cardiologist from Clinique Pasteur, Toulouse (France). "The improved deliverability of this new drug eluting stent system will allow us to treat the most challenging patients' anatomies with more confidence".
Additionally during the congress, the Ultimaster series of clinical results presented as 4 late breaking clinical trials, and in dozens different non sponsored scientific sessions have been drawing a considerable amount of interest among cardiologists. Moreover, the first interim analysis of recently finished e-Ultimaster global registry, which enrolled more than 37,000 patients in more than 400 hospitals worldwide have also been presented for the first time.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the health care market, and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
Corporate Communication Dept., Terumo Corporation
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.